BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX) from a neutral rating to a buy rating in a research note published on Friday morning, Marketbeat reports. The Goldman Sachs Group currently has $137.00 target price on the stock, up from their prior target price of $90.00.

BNTX has been the subject of several other research reports. UBS Group raised their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. TD Cowen reduced their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a research report on Monday, November 4th. HC Wainwright boosted their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $137.54.

BioNTech Stock Performance

BNTX stock opened at $108.73 on Friday. The business’s fifty day moving average is $112.26 and its 200-day moving average is $96.82. The company has a quick ratio of 7.40, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market cap of $25.85 billion, a P/E ratio of -51.78 and a beta of 0.26. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same quarter last year, the business posted $0.73 EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. Equities research analysts forecast that BioNTech will post -3.47 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the period. Covestor Ltd grew its position in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the last quarter. Midwest Professional Planners LTD. lifted its stake in BioNTech by 7.2% during the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after acquiring an additional 212 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in BioNTech by 2.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after acquiring an additional 223 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares during the period. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.